Table 3.

Adjusted gMean ratios for AUC and C _max of afatinib 50 mg (subjects with hepatic impairment versus controls), % with 90 % CI

Parameter and unit	Hepatic impairment group	gMean ratio (%) (90 % CI)a	Intraindividual gCV (%)b
AUC0–∞ (ng h/mL)	Mild	92.6 (68.0–126.3)	33.6
	Moderate	94.9 (72.3–124.5)	31.6
C max (ng/mL)	Mild	109.5 (82.7–144.9)	30.3
	Moderate	126.9 (86.0–187.2)	42.8
AUC0–tz (ng h/mL)	Mild	90.6 (66.9–122.7)	32.8
	Moderate	94.5 (71.6–124.8)	32.4

AUC _0–tz area under the drug plasma concentration–time curve from time 0 to the time of the last quantifiable data point, AUC _0–∞ area under the drug plasma concentration–time curve from time 0 to infinity, C _max maximum drug concentration in plasma, gCV geometric coefficient of variation (%), gMean geometric mean

^aRatio of gMeans (hepatic impairment subjects to healthy subjects). Statistical assessment of differences in pharmacokinetic parameters between patients with mild and moderate hepatic impairment and healthy subjects was performed using separate ANOVA models

^bSee Table 2 for the individual group means for each treatment group